Empagliflozin for treating chronic kidney disease (TA942)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 20 December 2023
Obinutuzumab for treating lupus nephritis TID6420Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Sparsentan for treating primary IgA nephropathy ID6308Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 11 December 2024
Targeted-release budesonide for treating primary IgA nephropathy (TA937)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 20 December 2023
Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease [ID3821]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 20 November 2024